Background Despite the importance of ST-segment elevation myocardial infarction (STEMI) in China, no nationally representative studies have characterised the clinical profi les, management, and outcomes of this cardiac event during the past decade. We aimed to assess trends in characteristics, treatment, and outcomes for patients with STEMI in China between 2001 and 2011.
Introduction
As China has grown economically, it has experienced an epidemiological transition, with mortality due to ischaemic heart disease more than doubling during the past two decades to more than 1 million deaths per year. 1, 2 This trend is expected to accelerate, with the World Bank estimating that the number of individuals with myocardial infarction in China will increase to 23 million by 2030. 3 Concurrent with this changing epidemiology, the Chinese medical care system has developed rapidly, implementing policies that have improved access by reducing fi nancial barriers and increasing the numbers of hospitals and physicians. 4, 5 Despite the importance of acute myocardial infarction in China-particularly ST-segment elevation myocardial infarction (STEMI), which accounts for more than 80% of such events in the country 6, 7 -no nationally representative studies have defi ned the clinical profi les, management, and outcomes of patients with this disorder during the past decade. The scarcity of contemporary national estimates and data for changes in burden of disease, quality of care (including use of recommended treatments and inappropriate use of non-evidence-based treatments), and treatment outcomes are important barriers to implementation of interventions to improve care and outcomes. In particular, little information is available about acute myocardial infarction in rural areas, where most of the Chinese population lives. [8] [9] [10] In the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), we aimed to assess trends in STEMI management and outcomes in China during the past decade in a retrospective analysis of hospital records. We selected representative hospitals from 2011 to assess present practices and traced this cohort of hospitals backwards to 2006 and 2001 to describe temporal changes.
Methods

Study design
The design of the China PEACE-Retrospective AMI Study has been described previously. 11 Briefl y, we used a two-stage random sampling design to create a nationally representative sample of patients in China admitted to hospital for acute myocardial infarction in 3 years (2001, 2006, and 2011 ). In the fi rst stage, we assessed all non-military hospitals in China and excluded prison hospitals, specialised hospitals without a division for cardiovascular disease, and hospitals for traditional Chinese medicine. We stratifi ed the remaining hospitals into fi ve economic-geographical regions (eastern rural, central rural, western rural, eastern urban, and central-western urban). We used these groups because hospital volumes and clinical capacities diff er between urban and rural areas and the three offi cial economicgeographical regions (eastern, central, and western) of mainland China. We grouped the central and western urban regions together because incomes and health services capacity per person are much the same. We randomly sampled all highest-level hospitals in urban regions and all central hospitals in rural regions, and excluded hospitals that did not admit patients with acute myocardial infarction or that declined to participate, to give the sample of participating hospitals.
In the second stage, we used systematic random sampling procedures to select for patients with acute myocardial infarction from the local hospital database of each sampled hospital in each study year. Patients with acute myocardial infarction were identifi ed according to International Classifi cation of DiseasesClinical Modifi cation codes, including versions 9 (410.xx) and 10 (I21.xx) when available, or through principal diagnosis terms noted at discharge. We collected data by central abstraction of medical charts with use of standardised data defi nitions. We used rigorous monitoring at each stage to ensure data quality. 11 Data abstraction quality was monitored by random auditing of 5% of the medical records, with overall variable accuracy exceeding 98%.
Participants
Only patients with a defi nite discharge diagnosis of STEMI were included in the study sample. The diagnosis of STEMI was determined by the combination of clinical discharge diagnosis terms and electrocardiogram (ECG) results. If the local diagnosis was not defi nitive, cardiologists at the coordinating centre reviewed the medical record and ECG to establish diagnosis. We treated left bundle branch block as a STEMI equivalent. The type of acute myocardial infarction was validated by review of ECGs from randomly selected records by a cardiologist not involved in data abstraction (appendix). We excluded all patients whose STEMI occurred during the course of the hospital admission.
The central ethics committee at the China National Center for Cardiovascular Diseases approved the China PEACE-Retrospective AMI Study. All collaborating hospitals accepted the central ethics approval except for fi ve hospitals, which obtained local approval by internal ethics committees.
Procedures
We abstracted data for the following patient characteristics: age, sex, cardiovascular risk factors, medical history, and clinical characteristics at admission. Information about the medical record abstraction has been described in detail previously. 11 Briefl y, comorbidities (including hypertension, diabetes, and dyslipidaemia) were defi ned as documented history in the admission notes, discharge diagnosis, or positive laboratory test results (total cholesterol >5·18 mmol/L or LDL ≥3·37 mmol/L, or HDL <1·04 mmol/L in men or <1·30 mmol/L in women).
We assessed clinical severity at admission from information collected at admission about systolic blood pressure, heart rate, estimated glomerular fi ltration rate, cardiac arrest, and cardiogenic shock. We also used the mini-Global Registry of Acute Coronary Events (mini-GRACE) risk score-a modifi ed version of the GRACE risk score including age, systolic blood pressure, ST-segment deviation, cardiac arrest at admission, elevated cardiac enzymes, and heart rate-which has been validated as a means of predicting 6-month mortality for STEMI. 12 We assessed use of treatments recommended by the 2010 China National Guideline for STEMI, 13 which are consistent with those recommended by guidelines in the USA.
14 These treatments included reperfusion therapy, aspirin within 24 h of admission, clopidogrel within 24 h of admission, β blockers within 24 h of admission, angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers during hospital admission, and statins during hospital admission. We assessed rates of use only in patients thought to be ideal for treatment, defi ned (consistent with previously studies) as patients without documented contraindications (appendix).
procedures, and tests. We included the seven main categories of traditional Chinese medicine used for coronary heart disease (appendix). We did not include some care processes (eg, counselling for smoking cessation) because of inadequate documentation.
We compared patients' in-hospital outcomes with four measures: death, death or withdrawal from treatment because of terminal status at discharge (referred to as treat ment withdrawal), composite complications (including death, treatment withdrawal, reinfarction, cardiogenic shock, ischaemic stroke, or congestive heart failure [defi ned in appendix]), and major bleeding. Treatment withdrawal is common in China because of reluctance by many patients to die in hospital. The Chinese Government uses in-hospital death or treatment withdrawal as a quality measure for hospitals. 18, 19 Cardiologists in the coordinating study centre adjudicated the clinical status of patients who withdrew from treatment on the basis of medical records. Major bleeding included any intracranial bleeding, absolute For the main analysis of in-hospital outcomes, we excluded patients who were transferred in from another hospital because we sought to characterise patients admitted directly to the hospital. We also excluded patients who were transferred out, because their admissions were truncated. We further excluded patients who were discharged alive within 24 h because they probably left against medical advice and there was very little time for treatment. For the analysis of treatments, procedures, and tests, we excluded patients who had transferred in from other hospitals, or who had a length of stay of 24 h or shorter.
Statistical analysis
To estimate nationally representative rates for each study year, we applied weights proportional to the inverse sampling fraction of hospitals within each stratum and the sampling fraction of patients within each hospital to account for diff erences in the sampling fraction for each period in all analyses. We examined patient characteristics, treatments, tests, procedures, and crude rate of outcomes across diff erent study years using the CochranArmitage trend test for the trend of binary variables, and the Mann-Kendall trend test for trends of continuous variables. All trend tests were based on three timepoints (2001, 2006, and 2011) . We used percentages with 95% CIs to describe categorical variables and medians with IQRs to describe continuous variables. We calculated the rate of hospital admissions due to STEMI in China in each study year by estimating the number of patients admitted to hospital for STEMI and dividing by the total population in the corresponding year; 1·23 billion people lived in China in 2001, 1·29 billion in 2006, and 1·34 billion in 2011. 8- 10 We imputed missing age values as the median age of the known set.
We constructed two indicator variables representing years 2006 and 2011, leaving 2001 as the reference. We did logistical regressions including these indicators for time as key explanatory variables, while adjusting for patients' demographics (age and sex), risk factors or medical history (hypertension, diabetes, current smoker, previous myocardial infarction, previous coronary heart disease, and previous stroke), and clinical characteristics at admission (chest discomfort, cardiac arrest, acute stroke, heart rate, systolic blood pressure, and symptom onset to admission time). To account for clustering of patients within hospitals, we established multilevel logistical regression models with use of generalised estimating equations. The dependent variables were in-hospital death, in-hospital death or treatment withdrawal, and in-hospital composite complications, respectively. We transformed continuous variables (eg, age, heart rate, and systolic blood pressure) into categorical variables according to clinically meaning ful cutoff values (appendix). We also tested the linear trend over time in the models. We report odds ratios (ORs) and 95% CIs from the multilevel logistical regression related to the year indicators.
We did a sensitivity analysis with adjustment according to mini-GRACE risk score. To account for patients without a mini-GRACE risk score because of missing measurement of cardiac enzymes, we used two methods. The fi rst method was to exclude these patients. Our other technique was to use the multiple imputation method to impute the variable (yes or no) for missing elevated cardiac enzymes so that the mini-GRACE risk score could be calculated. 20, 21 We also did a sensitivity analysis in the entire study sample. In view of the small decrease in length of hospital stay over time, we compared the results with the results with 7-day outcomes instead of the original outcomes.
All comparisons were two-sided, with statistical signifi cance defi ned as p less than 0·05. All p values are for trend. Statistical analysis was done with SAS software, version 9.2, and R software, version 3.0.2. The study is registered with ClinicalTrials.gov, number NCT01624883.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author has full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
According to government documents, China had 6623 non-military hospitals in 2011 (fi gure 1). We excluded 23 prison hospitals, 687 specialised hospitals without divisions for cardiovascular disease, and 1692 hospitals for traditional Chinese medicine. The sampling framework comprised 2010 central hospitals in 2010 rural regions in three rural strata, and 833 highest-level hospitals in 287 urban regions in two urban strata. PCI=percutaneous coronary intervention. ACE=angiotensin-converting enzyme. STEMI=ST-segment elevation myocardial infarction. Data are n/N or weighted % (95% CI), for which n is the number of patients in the study sample and weighted % is a nationally representative rate, unless otherwise stated. *Only among ideal patients for the treatment (ie, patients with no documented contraindications). †During hospital admission. ‡Among patients who received at least one stent. (table 2) . By contrast, the use of traditional Chinese medicine within 24 h and at any time during hospital admission increased (table 2) .
The weighted proportion of patients that underwent cardiac catheterisation, underwent non-primary percutaneous coronary intervention, or received drug-eluting stents also increased between 2001 and 2011 (table 2). The proportion of patients that underwent coronary artery bypass graft surgery was very small (14 After adjustment for patient demographic and clinical characteristics in the multilevel logistical regression, the risk of in-hospital mortality did not signifi cantly decrease over time (fi gure 3). Similarly, the adjusted risk of death or treatment withdrawal and complications did not change over time (fi gure 3). Adjusted outcomes calculated with a 7-day timeframe were much the same as the primary analyses using the entire hospital stay (fi gure 4). A sensitivity analysis compared the results of the entire cohort with those of the population excluding transferred patient. The results of these two analyses did not diff er ( appendix).
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Discussion
In the China PEACE-Retrospective AMI Study we aimed to document changes in the clinical profi les, treatment Retracted paper, errors highlighted
Articles patterns, quality of care, and in-hospital mortality of patients admitted to hospital for STEMI in China during the past decade. This study, funded by the Chinese Government, was designed to generate the knowledge to support future national initiatives to improve STEMI care and patient outcomes in China. Our study of a nationally representative sample of patients between 2001 and 2011 characterises the trends in the epidemiology, treatment, and outcomes of patients with STEMI. We identifi ed substantial increases in the estimated national rate of hospital admission for STEMI. Furthermore, we identifi ed a growing burden of prevalent coronary risk factors, persistent delays in admission to hospital, increasing use of procedures and tests, relatively long hospital stays, and gaps in quality of care with the underuse of guideline-recommended therapies and the use of therapies of unknown eff ectiveness. Concurrent with these trends, outcomes have not improved. To our knowledge, the China PEACE-Retrospective AMI Study is the fi rst large study with rigorous random sampling of a hospital cohort to study national trends in STEMI in China (panel), and identifi es important opportunities for quality improvement and policy making. 11 Because of the random sampling strategy used to identify hospitals and patients in our study, we believe that the results represent practice in China in general-a large country with great variations across regions and hospitals. 23 The experience in China, with the growth in admissions for STEMI, the gaps in treatment, and the growing complexity of patients is similar to previous experience in the USA. This study, like the Cooperative Cardiovascular Project (CCP) 24 undertaken 20 years ago in the USA, provides important information about opportunities for improvement. Since the CCP, the USA has invested substantially in quality improvement for cardiovascular disease and has had marked improvements in admission rates, and process of care and outcomes for acute myocardial infarction. [25] [26] [27] [28] The economic transition in China is resulting in more non-communicable diseases such as STEMI, which has substantial implications for the strategies needed to develop the health-care system. The growing needs for inpatient STEMI care will create pressure for Chinese hospitals to increase capacity, adequately train health-care pro fessionals, develop infrastructure, and improve care. The striking increases in hospital admissions for STEMI noted in our study show that important improvements in capacity have been made; however, national STEMI mortality 5 suggests that further growth will be necessary to ensure adequate access for patients with the disorder in China. Furthermore, our study underlines that access to care does not ensure the delivery of the highest-quality care; suggesting that in addition to improvements in capacity, hospitals in China must simultaneously strive to improve care.
The quality of care has improved during the past decade, but substantial gaps still persist. Increases in the use of aspirin, clopidogrel, and statins are encouraging. However, β blockers and angiotensin-converting-enzyme inhibitors, which reduce mortality in patients with STEMI, remain very underused. Only half of ideal candidates for reperfusion therapy received treatment, a proportion that did not improve over time. This fi nding suggests that obstacles persist-eg, diffi culty in identifi cation of ideal patients, balancing of the risks and benefi ts of treatment, and the growing proportion of comorbidities-that render treatment more challenging. Gaps in care might also result from inadequate provider knowledge, structural inadequacies of the systems of care, or concern about potential patient disputes and litigation due to risk of treatment. [29] [30] [31] Our fi ndings underscore the need for national initiatives to understand the reasons for persistent gaps in care and improve the use of evidence-based care for STEMI in China. 32, 33 Importantly, our results raise a particular concern that the increased intensity of treatment, procedure use, and testing has not been associated with major decrements in mortality between 2001 and 2011. Moreover, this change occurred in the context of a decrease in length of stay over time. The reported inhospital mortality in our representative study is consistent with a large trial of 46 000 Chinese patients, but is higher than that reported in two prospective studies with non-randomly selected patients admitted to hospital between 2004 and 2006. 6, 7, 22 By contrast with the improvement achieved in a similar period in the USA and the UK, the lack of change in mortality in China suggests an opportunity for quality
Panel: Research in context
Systematic review
We searched PubMed for articles published in English and Chinese between Jan 1, 2000, and March 12, 2014, with the terms "ST-segment elevation myocardial infarction", "acute myocardial infarction", "acute coronary syndrome", and "China". We identifi ed three large nationwide studies, one a clinical trial undertaken in 1999-2005, 6 and the other two observational studies. Both observational studies used a convenience sample of hospitals. One studied 2973 patients with acute coronary syndrome from 51 hospitals between 2004 and 2005. 7 The other study included 3323 patients with acute coronary syndrome from 65 hospitals in 2006. 22 
Interpretation
To our knowledge, this study, which included 13815 patients from 162 randomly selected hospitals across China, is the fi rst nationally representative investigation of ST-segment elevation myocardial infarction (STEMI). We studied the trends in admissions, the clinical profi les, quality of care, and outcomes of STEMI between 2001 and 2011, a period of epidemiological transition. We noted that hospital admissions for STEMI have become increasingly common, patients are more likely to have comorbidities, and the intensity of testing and treatment has increased. Quality of care has improved for some treatments, but important gaps persist and in-hospital mortality has not signifi cantly improved. Policy makers and health professionals in China have opportunities to improve quality care and outcomes for patients with STEMI and to work to slow the rise in these events.
Retracted paper, errors highlighted improvement. 27, 34 If the in-hospital mortality of STEMI could be reduced by 1% in China, at least 2100 lives could be saved every year. The number of lives saved would rise rapidly if the number of STEMI increases, as is anticipated. Our data do not show signifi cant improvement in mortality between 2001 and 2011, but we cannot exclude a meaningful eff ect in view of the point estimates and confi dence intervals. Comparison of mini-GRACE-adjusted mortality rates between 2001 and 2011 suggested a borderline-signifi cant reduction in in-hospital mortality, but when treatment withdrawal was included the results were not signifi cant and the point estimate did not suggest a benefi t. In China, many patients withdraw from treatment at terminal status, which could be attributed to culture or aff ordability. Therefore, a focus on in-hospital mortality alone, without accounting for these patients, could result in an underestimate of actual short-term mortality rates. Nevertheless, we cannot exclude the possibility that a modest benefi t occurred based on the confi dence intervals.
Several factors could account for why mortality did not improve signifi cantly. First, we noted little improvement in the time from symptom onset to hospital admission, which is much longer than that reported in other national databases. 35, 36 Second, rates of reperfusion therapies, which were much lower than are those in the USA or Europe, did not improve. 28, 37 Third, the rate of primary percutaneous coronary intervention was still low in 2011 despite an increase during the past decade. 28, 37 This rate, in particular, might be able to be increased in some settings but not others. Improvement of these three factors alone could substantially reduce mortality. 38 Fourth, we did detect increasing rates of cardiac arrest and cardiogenic shock, which is a concern, but they did not account for the lack of substantial improvement in mortality.
We also noted that several therapies that are known to be ineff ective, or lack strong evidence, are often given in China. About a sixth of patients received magnesium sulfate, despite a large body of evidence that this therapy is either ineff ective or could cause harm. 16, 17 Traditional Chinese medicine is increasingly used, despite little evidence of its effi cacy and safety for treatment of STEMI. 39 Further research is needed to elucidate the clinical benefi t of traditional Chinese medicine for the management of STEMI.
The fi ndings of this study should be interpreted in view of several limitations. First, the lack of regular biomarker measurement, particularly in 2001, precludes a gold-standard diagnosis of STEMI. Increasing use of biomarker-based diagnosis would likely increase the number of less severe cases in our cohort in 2006 and 2011. 13, 40, 41 This change would be expected to bias towards improvements in outcomes in 2006 and 2011, but we noted no diff erence. The early years of our cohort might have included more patients without STEMI, but we collected detailed information about clinical condition and no evidence suggested that the risk based on the initial vital signs and clinical condition changed importantly over time. Second, we measured clinical characteristics on the basis of documentation in medical records. Defi nitions of some disorders and completeness of documentation can diff er across hospitals and over time. Third, we could only measure in-hospital outcomes, which might vary from those measured with use of a standardised timeframe (eg, 30 days), 42 because we were unable to link patient-level data to a national registry of deaths. Nevertheless, the long length of stay in China permits a fairly long observation period for patients admitted to hospital. Furthermore, analysis with a standardised 7-day timeframe did not provide diff erent results from the primary analysis. Fourth, the use of laboratory tests, including measurement of cardiac biomarkers and creatinine, is inconsistent in China, which might have aff ected our fi ndings. However, the risk factors that were available for all patients predicted mortality very well and were probably suffi cient for comparisons over time. 12 Fifth, the study was not powered to detect trends in mortality and our study cannot exclude the possibility of a meaningful improvement in mortality during the study period. However, we detected no strong indication of improvement, especially when we took into account patients who had treatment withdrawn. Finally, we cannot comment on patients with STEMI who were not admitted to hospital during the study period, and we cannot establish whether the increase in the number of patients admitted to hospital with STEMI over time represented increased access to health care or an increasing prevalence of STEMI in the population (or both). Nevertheless, to our knowledge this study is the most comprehensive of patients admitted to hospital with STEMI during the past decade in China.
Our study showed that, among patients admitted to hospital with STEMI, persistent gaps are present between practice and recommended care and outcomes have not signifi cantly improved during the past decade. Although China has launched health-care reform and recently doubled annual expenditures for health care to improve access, challenges exist in optimisation of the use of scarce resources to provide the highest-quality care. Our fi ndings provide evidence for policy makers and health professionals in China and other countries with a rapidly growing burden of STEMI to inform future strategies for medical resource allocation, system improvement, and disease management. 
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Introduction
As China has grown economically, it has experienced an epidemiological transition, with mortality due to ischaemic heart disease more than doubling during the past two decades to more than 1 million deaths per year. 1, 2 This trend is expected to accelerate, with the World Bank estimating that the number of individuals with myocardial infarction in China will increase to 23 million by 2030. 3 Concurrent with this changing epidemiology, the Chinese medical care system has developed rapidly, implementing policies that have improved access by reducing fi nancial barriers and increasing the numbers of hospitals and physicians. 4, 5 Despite the importance of acute myocardial infarction in China-particularly ST-segment elevation myocardial infarction (STEMI), which accounts for more than 80% of such events in the country 6, 7 -no nationally representative studies have defi ned the clinical profi les, management, and outcomes of patients with this disorder during the past decade. The scarcity of contemporary national estimates and data for changes in burden of disease, quality of care (including use of recommended treatments and inappropriate use of non-evidence-based treatments), and treatment outcomes are important barriers to implementation of interventions to improve care and outcomes. In particular, little information is available about acute myocardial infarction in rural areas, where most of the Chinese population lives.
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In the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), we aimed to assess trends in STEMI management and outcomes in China during the past decade in a retrospective analysis of hospital records. We selected representative hospitals from 2011 to assess present practices and traced this cohort of hospitals backwards to 2006 and 2001 to describe temporal changes.
Methods
Study design
The design of the China PEACE-Retrospective AMI Study has been described previously. 11 Briefl y, we used a two-stage random sampling design to create a nationally representative sample of patients in China admitted to hospital for acute myocardial infarction in 3 years (2001, 2006 , and 2011). In the fi rst stage, we assessed all non-military hospitals in China and excluded prison hospitals, specialised hospitals without a division for cardiovascular disease, and hospitals for traditional Chinese medicine. We stratifi ed the remaining hospitals into fi ve economic-geographical regions (eastern rural, central rural, western rural, eastern urban, and central-western urban). We used these groups because hospital volumes and clinical capacities diff er between urban and rural areas and the three offi cial economicgeographical regions (eastern, central, and western) of mainland China. We grouped the central and western urban regions together because incomes and health services capacity per person are much the same. We randomly sampled all highest-level hospitals in urban regions and all central hospitals in rural regions, and excluded hospitals that did not admit patients with acute myocardial infarction or that declined to participate, to give the sample of participating hospitals.
In the second stage, we used systematic random sampling procedures to select for patients with acute myocardial infarction from the local hospital database of each sampled hospital in each study year. Patients with acute myocardial infarction were identifi ed according to International Classifi cation of DiseasesClinical Modifi cation codes, including versions 9 (410.xx) and 10 (I21.xx) when available, or through principal diagnosis terms noted at discharge. We collected data by central abstraction of medical charts with use of standardised data defi nitions. We used rigorous monitoring at each stage to ensure data quality.
11 Data abstraction quality was monitored by random auditing of 5% of the medical records, with overall variable accuracy exceeding 98%.
Participants
Only patients with a defi nite discharge diagnosis of STEMI were included in the study sample. The diagnosis of STEMI was determined by the combination of clinical discharge diagnosis terms and electrocardiogram (ECG) results. If the local diagnosis was not defi nitive, cardiologists at the coordinating centre reviewed the medical record and ECG to establish diagnosis. We treated left bundle branch block as a STEMI equivalent. The type of acute myocardial infarction was validated by review of ECGs from randomly selected records by a cardiologist not involved in data abstraction (appendix 2). We excluded all patients whose STEMI occurred during the course of the hospital admission.
Procedures
14 These treatments included reperfusion therapy, aspirin within 24 h of admission, clopidogrel within 24 h of admission, β blockers within 24 h of admission, angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers during hospital admission, and statins during hospital admission. We assessed rates of use only in patients thought to be ideal for treatment, defi ned (consistent with previously studies) as patients without documented contraindications (appendix 2). 15 We also assessed the use of magnesium sulfate (a treatment that is ineff ective), 16, 17 traditional Chinese medicine, other
See Online for appendix Republished paper, new data highlighted procedures, and tests. We included the seven main categories of traditional Chinese medicine used for coronary heart disease (appendix 2). We did not include some care processes (eg, counselling for smoking cessation) because of inadequate documentation. We compared patients' in-hospital outcomes with four measures: death, death or withdrawal from treatment because of terminal status at discharge (referred to as treat ment withdrawal), composite complications (including death, treatment withdrawal, reinfarction, cardiogenic shock, ischaemic stroke, or congestive heart failure [defi ned in appendix 2]), and major bleeding. Treatment withdrawal is common in China because of reluctance by many patients to die in hospital. The Chinese Government uses in-hospital death or treatment withdrawal as a quality measure for hospitals. 18, 19 Cardiologists in the coordinating study centre adjudicated the clinical status of patients who withdrew from treatment on the basis of medical records. Major bleeding included any intracranial bleeding, absolute For the main analysis of in-hospital outcomes, we excluded patients who were transferred in from another hospital because we sought to characterise patients admitted directly to the hospital. We also excluded patients who were transferred out, because their admissions were truncated. We further excluded patients who were discharged alive within 24 h because they probably left against medical advice and there was very little time for treatment. For the analysis of treatments, procedures, and tests, we excluded patients who had transferred in from other hospitals, or who had a length of stay of 24 h or shorter.
Statistical analysis
To estimate nationally representative rates for each study year, we applied weights proportional to the inverse sampling fraction of hospitals within each stratum and the sampling fraction of patients within each hospital to account for diff erences in the sampling fraction for each period in all analyses. We examined patient characteristics, treatments, tests, procedures, and crude rate of outcomes across diff erent study years using the CochranArmitage trend test for the trend of binary variables, and the Mann-Kendall trend test for trends of continuous variables. All trend tests were based on three timepoints (2001, 2006, and 2011) . We used percentages with 95% CIs to describe categorical variables and medians with IQRs to describe continuous variables. We calculated the rate of hospital admissions due to STEMI in China in each study year by estimating the number of patients admitted to hospital for STEMI and dividing by the total population in the corresponding year; 1·27 billion people lived in China in 2001, 1·31 billion in 2006, and 1·34 billion in 2011. 8- 10 We imputed missing age values as the median age of the known set.
We constructed two indicator variables representing years 2006 and 2011, leaving 2001 as the reference. We did logistic regressions including these indicators for time as key explanatory variables, while adjusting for patients' demographics (age and sex), risk factors or medical history (hypertension, diabetes, current smoker, previous myocardial infarction, previous coronary heart disease, and previous stroke), and clinical characteristics at admission (chest discomfort, cardiac arrest, acute stroke, heart rate, systolic blood pressure, and symptom onset to admission time). To account for clustering of patients within hospitals, we established multilevel logistic regression models with use of generalised estimating equations. The dependent variables were in-hospital death, in-hospital death or treatment withdrawal, and in-hospital composite complications, respectively. We transformed continuous variables (eg, age, heart rate, and systolic blood pressure) into categorical variables according to clinically meaning ful cutoff values (appendix 2). We also tested the linear trend over time in the models. We report odds ratios (ORs) and 95% CIs from the multilevel logistic regression related to the year indicators.
Role of the funding source
Results
According to government documents, China had 6623 non-military hospitals in 2011 (fi gure 1). We excluded 23 prison hospitals, 687 specialised hospitals without divisions for cardiovascular disease, and 1692 hospitals for traditional Chinese medicine. The sampling framework comprised 2010 central hospitals in 2010 rural regions in three rural strata, and 833 highest-level hospitals in 287 urban regions in two urban strata. GRACE=Global Registry of Acute Coronary Events. Data are median (IQR) or n (weighted % [95% CI]), for which n is the number of patients in the study sample and weighted % is a nationally representative rate. STEMI=ST-segment elevation myocardial infarction. *Among patients with measurements available. 
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We sampled 175 hospitals and invited them to participate in the study. Seven hospitals (two rural and fi ve urban) were excluded because they did not admit patients with acute myocardial infarction and six (four rural, two urban) declined to participate. Examination of patient databases from the 162 remaining hospitals yielded 31 601 hospital admissions for acute myocardial infarction (3859 in 2001, 8863 in 2006, and 18 879 in 2011). We sampled 18 631 cases and acquired medical records for 18 110 (97·2%) cases (fi gure 1). We excluded 4295 cases that did not meet the study criteria to create the study sample of 13 815 patients admitted to hospital for STEMI. Between 2001 and 2011, the age and sex of patients admitted to hospital for STEMI did not change (table 1) . Information about age was missing for 18 (0·1%) patients. In 2011, the median age was 65 years (IQR 55-74), and 2247 of 7696 patients (weighted rate 29·5%, 95% CI 28·4-30·5) were women. Risk factors for cardiovascular disease and previous atherosclerotic events increased in prevalence over time (table 1) .
The median time between symptom onset and hospital admission did not change between 2001 and 2011 (table 1) . Between 2001 and 2011, patients became less likely to present with hypotension, tachycardia, ejection fraction of 0·40 or less, or low estimated glomerular fi ltration rate (table 1). The prevalence of cardiac arrest and cardiogenic shock increased slightly. The median troponin concentration increased over time. Mini-GRACE scores did not diff er across the study period.
After exclusion of 559 patients transferred in from other facilities (37 in PCI=percutaneous coronary intervention. ACE=angiotensin-converting enzyme. STEMI=ST-segment elevation myocardial infarction. Data are n/N or weighted % (95% CI), for which n is the number of patients in the study sample and weighted % is a nationally representative rate, unless otherwise stated. *Only among ideal patients for the treatment (ie, patients with no documented contraindications). †During hospital admission. ‡Among patients who received at least one stent. (table 2) . By contrast, the use of traditional Chinese medicine within 24 h and at any time during hospital admission increased (table 2) .
The weighted proportion of patients that underwent cardiac catheterisation, underwent non-primary percutaneous coronary intervention, or received drug-eluting stents also increased between 2001 and 2011 (table 2). The proportion of patients that underwent coronary artery bypass graft surgery was very small (14 of 1995 After adjustment for patient demographic and clinical characteristics in the multilevel logistic regression, the risk of in-hospital mortality did not signifi cantly decrease over time (fi gure 3). Similarly, the adjusted risk of death or treatment withdrawal and complications did not change over time (fi gure 3). Adjusted outcomes calculated with a 7-day timeframe were much the same as the primary analyses using the entire hospital stay (fi gure 4). A sensitivity analysis compared the results of the entire cohort with those of the population excluding transferred patient. The results of these two analyses did not diff er ( appendix 2).
Discussion
In the China PEACE-Retrospective AMI Study we aimed to document changes in the clinical profi les, treatment Republished paper, new data highlighted Articles patterns, quality of care, and in-hospital mortality of patients admitted to hospital for STEMI in China during the past decade. This study, funded by the Chinese Government, was designed to generate the knowledge to support future national initiatives to improve STEMI care and patient outcomes in China. Our study of a nationally representative sample of patients between 2001 and 2011 characterises the trends in the epidemiology, treatment, and outcomes of patients with STEMI. We identifi ed substantial increases in the estimated national rate of hospital admission for STEMI. Furthermore, we identifi ed a growing burden of prevalent coronary risk factors, persistent delays in admission to hospital, increasing use of procedures and tests, relatively long hospital stays, and gaps in quality of care with the underuse of guideline-recommended therapies and the use of therapies of unknown eff ectiveness. Concurrent with these trends, outcomes have not improved. To our knowledge, the China PEACE-Retrospective AMI Study is the fi rst large study with rigorous random sampling of a hospital cohort to study national trends in STEMI in China (panel), and identifi es important opportunities for quality improvement and policy making.
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Because of the random sampling strategy used to identify hospitals and patients in our study, we believe that the results represent practice in China in general-a large country with great variations across regions and hospitals. 23 The experience in China, with the growth in admissions for STEMI, the gaps in treatment, and the growing complexity of patients is similar to previous experience in the USA. This study, like the Cooperative Cardiovascular Project (CCP) 24 undertaken 20 years ago in the USA, provides important information about opportunities for improvement. Since the CCP, the USA has invested substantially in quality improvement for cardiovascular disease and has had marked improvements in admission rates, and process of care and outcomes for acute myocardial infarction. [25] [26] [27] [28] The economic transition in China is resulting in more non-communicable diseases such as STEMI, which has substantial implications for the strategies needed to develop the health-care system. The growing needs for inpatient STEMI care will create pressure for Chinese hospitals to increase capacity, adequately train health-care pro fessionals, develop infrastructure, and improve care. The striking increases in hospital admissions for STEMI noted in our study show that important improvements in capacity have been made; however, national STEMI mortality 5 suggests that further growth will be necessary to ensure adequate access for patients with the disorder in China. Furthermore, our study underlines that access to care does not ensure the delivery of the highest-quality care; suggesting that in addition to improvements in capacity, hospitals in China must simultaneously strive to improve care.
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improvement. 27, 34 If the in-hospital mortality of STEMI could be reduced by 1% in China, at least 2100 lives could be saved every year. The number of lives saved would rise rapidly if the number of STEMI increases, as is anticipated. Our data do not show signifi cant improvement in mortality between 2001 and 2011, but we cannot exclude a meaningful eff ect in view of the point estimates and confi dence intervals. Comparison of mini-GRACE-adjusted mortality rates between 2001 and 2011 suggested a borderline-signifi cant reduction in in-hospital mortality, but when treatment withdrawal was included the results were not signifi cant and the point estimate did not suggest a benefi t. In China, many patients withdraw from treatment at terminal status, which could be attributed to culture or aff ordability. Therefore, a focus on in-hospital mortality alone, without accounting for these patients, could result in an underestimate of actual short-term mortality rates. Nevertheless, we cannot exclude the possibility that a modest benefi t occurred based on the confi dence intervals.
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